Ralph Steven Baric

This study identifies Aminopeptidase N as the receptor for hedgehog merbecoviruses and shows restricted cross-species receptor use.

The paper investigates how IGHV3-53/3-66 antibodies from Omicron BA.1 infection neutralize emerging SARS-CoV-2 variants through structural and mutational analysis.

Epitope-focused S2 stem-helix nanoparticle immunogens elicit protective broadly neutralizing antibodies against diverse betacoronaviruses in non-human primates, establishing a framework for pan-betacoronavirus vaccines.

This study maps H2 influenza virus antigens recognized by ferret and human sera, revealing differences in antigen clustering and predicting antigenically significant sites.

The paper identifies a broadly neutralizing antibody targeting the S2 subunit of sarbecoviruses, revealing a conserved site of vulnerability in the spike protein.

This study shows that SARS-CoV-2 with impaired nsp14-exonuclease activity has reduced replication, fitness, and pathogenesis, but remains viable in some conditions.

The paper identifies immune mediators linking host susceptibility loci to disease severity across SARS-CoV and SARS-CoV-2 infections.

This study isolates and characterizes neutralizing antibodies against HCoV-229E, showing one antibody induces conformational changes in the viral spike protein.

This study infects 5xFAD mice with SARS-CoV-2 and finds no change in Alzheimer's pathology but widespread gene expression changes in multiple cell types.

This study identifies a monoclonal antibody that neutralizes HCoV-HKU1 by mimicking sialic acid binding to block receptor engagement.

This study identifies mAbs targeting HCoV-HKU1 spike protein and shows that receptor-binding site recognition alone does not predict neutralization in primary cells.

This study identifies structural and phenotypic changes in the RBD loop2 region of HKU5r-CoVs as key factors enabling their emergence in mink and potential zoonotic transmission.

This paper develops an mRNA-launched nanoparticle vaccine that combines protein nanoparticle and mRNA vaccine advantages, showing enhanced antibody and T cell responses in mice.

This study identifies sex differences in long COVID sequelae in mice, showing that X-linked genes like Xist and Tlr7 contribute to persistent inflammation and cognitive impairments in females.

This study examines SARS-CoV-2 infection and repair responses in human airway epithelial cells, finding prolonged and incomplete repair linked to long-COVID pulmonary symptoms.

This paper develops a mouse model of SARS-CoV-2 BA.5 infection that induces fibrotic lung disease and tertiary lymphoid structures, enabling study of acute and post-acute sequelae of COVID-19.

Non-stabilized SARS-CoV-2 Spike mRNA vaccination in macaques induces B cell lineages targeting conserved epitopes on Omicron variants or cross-neutralizing epitopes on Sarbecoviruses.

This study designs miniproteins that inhibit MERS-CoV by targeting the spike protein, showing broad neutralization and protective efficacy in mice.

The paper identifies ACE2 as a receptor for HKU5 coronaviruses from Pipistrellus abramus bats and investigates receptor tropism across merbecovirus clades.

This paper designs multivalent RBD nanoparticle vaccines that overcome immune imprinting and provide broad protection against SARS-CoV-2 variants and sarbecoviruses.

This study develops methods to culture human and animal airway explants for at least 14 days, preserving tissue architecture and enabling study of health, disease, and viral infection.

This study evaluates a stabilized DENV2 E homodimer vaccine, finding it elicits broader neutralizing antibody responses targeting multiple E protein domains compared to the wild-type monomer.

This study identifies bat and mink ACE2 as receptors for HKU5 merbecovirus, revealing distinct receptor interactions and highlighting mustelids as potential intermediate hosts.

This study uses multi-omics analysis to show that dysregulated lung epithelial cell homeostasis and immune responses drive severe MERS-CoV disease in mice.

This study develops MERS-CoV vaccines using a protein nanoparticle platform, showing they induce strong neutralizing antibodies and protect mice against MERS-CoV challenge.

The paper updates the MiniMUGA genotyping array's bioinformatic pipeline to enhance genetic QC in laboratory mice by improving marker annotation, consensus genotypes, and report usability.

This study compares IgG antibody responses from SARS-CoV-2 infection, vaccination, and hybrid immunity, finding that hybrid immunity retains the imprint of the initial exposure and enhances antibody breadth and affinity.

This paper develops a stabilization strategy for sarbecovirus fusion machinery vaccines, showing broad reactivity and protection against SARS-CoV-2 variants.

The paper identifies a genetic locus associated with coronavirus disease susceptibility in mice and shows its relevance to human severe COVID-19 outcomes.

This paper demonstrates that MM3122, a host cell serine protease inhibitor, effectively inhibits SARS-CoV-2 replication and reduces disease severity in mice, both prophylactically and therapeutically.